NTRK1 and cancer: As illustrated in Fig. 6A–D and F, we found that the IC50 values of several anti-LUAD drugs decreased in the high-DLGAP5 group, including chemotherapeutic drugs (cisplatin, paclitaxel, docetaxel), EGFR inhibitor (gefitinib) and receptor tyrosine kinase (RTK) inhibitor (crizotinib), revealing that patients with high DLGAP5 expression were relatively sensitive to these anti-cancer drugs.